Selected article for: "high level and small percentage"

Author: Birhane, Meseret; Bressler, Sara; Chang, Gregory; Clark, Thomas; Dorough, Layne; Fischer, Marc; Watkins, Louise Francois; Goldstein, Jason M.; Kugeler, Kiersten; Langley, Gayle; Lecy, Kristin; Martin, Stacey; Medalla, Felicita; Mitruka, Kiren; Nolen, Leisha; Sadigh, Katrin; Spratling, Robin; Thompson, Gail; Trujillo, Alma
Title: COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
  • Cord-id: oi8epg9m
  • Document date: 2021_5_28
  • ID: oi8epg9m
    Snippet: COVID-19 vaccines are a critical tool for controlling the ongoing global pandemic. The Food and Drug Administration (FDA) has issued Emergency Use Authorizations for three COVID-19 vaccines for use in the United States.* In large, randomized-controlled trials, each vaccine was found to be safe and efficacious in preventing symptomatic, laboratory-confirmed COVID-19 (1-3). Despite the high level of vaccine efficacy, a small percentage of fully vaccinated persons (i.e. received all recommended dos
    Document: COVID-19 vaccines are a critical tool for controlling the ongoing global pandemic. The Food and Drug Administration (FDA) has issued Emergency Use Authorizations for three COVID-19 vaccines for use in the United States.* In large, randomized-controlled trials, each vaccine was found to be safe and efficacious in preventing symptomatic, laboratory-confirmed COVID-19 (1-3). Despite the high level of vaccine efficacy, a small percentage of fully vaccinated persons (i.e. received all recommended doses of an FDA-authorized COVID-19 vaccine) will develop symptomatic or asymptomatic infections with SARS-CoV-2, the virus that causes COVID-19 (2-8).

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1
    Co phrase search for related documents, hyperlinks ordered by date